Frontline inotuzumab ozogamicin in older adults with Philadelphia chromosome-negative B-ALL: an exploratory pooled analysis of efficacy and safety
Older adults (aged ≥ 55 years) with Philadelphia chromosome-neg-ative B-cell acute lymphoblastic leukemia (B-ALL) frequently present with adverse cytogenetic features, poor treatment tolerance, and inferior long-term outcomes [1, 2]. While intensive chemotherapy remains the standard first-line approach, its clinical ef...